Abeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation and a newly licensed prostate cancer cell therapy program during the company’s earnings call.
Chief Executive Officer Dr. Vishwas Seshadri said Abeona has treated five commercial patients with ZEVASKYN since the product’s launch, with manufacturing underway for a sixth patient and additional patients scheduled during the current quarter. Three ZEVASKYN treatments occurred in the first quarter, generating $8.7 million in net product revenue.
